A Practical Guide to Managing Less Common Immune-Related Adverse Events: Slides

Download these slides to learn how an expert manages less common immune-related adverse events including neurologic, cardiac, and more, and then review expert answers to common questions about optimal toxicity management.
Jeffrey S. Weber, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.06 MB
Released: March 23, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.

Related Content

GeparNUEVO survival outcomes with durvalumab + neoadjuvant chemo in early triple-negative breast cancer from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 10, 2021

Interactive online tool with expert recommendations for assessing and managing adverse events associated with BTK inhibitors, from Clinical Care Options

Farrukh T. Awan, MD Christopher R. Flowers, MD, MS Nicole Lamanna, MD John P. Leonard, MD Julie M. Vose, MD, MBA Released: June 9, 2021

Phase II study of niraparib with/without dostarlimab shows a CBR of 31.8% vs 20.0% with monotherapy in recurrent EC from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 8, 2021

In this slideset from Clinical Care Options (CCO), experts review best practices in counseling patients and caregivers on CAR T-cell therapy

Jacklyn Gideon, MSN, AGPCNP-BC Released: May 27, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue